Medical Articles
Click on the links to view each article.
MESOTHELIOMA ARTICLES
Dihydro-5 Azacitadine.pdf
Edatrexate with or without Leucovorin rescue for malignant mesothelioma.pdf
Factors Predictive of Survival among 337 Patients with Mesothelioma treatment.pdf
High Dose Paclitaxel plus C-CSF for malignant mesothelioma.pdf
Impact of tumor size on the clinical outcomes of patients with robson stage 1 renal cell carcinoma.pdf
Multicenter phase II trial of neoadjuvent Pemetrexed.pdf
New Agents in the Management of Malignant Mesothelioma.pdf
Newer Issues in Mesothelioma CHemotherapy.pdf
Phase II Trial of a single weekly intravaneous dose of Ranpirane.pdf
Regarding a multicenter phase II study of gemcitabine and Oxaliplatin for malignant pleural mesothelioma.pdf
Second Line Chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin.pdf
Standard Therapy for the treatment of pleural mesothelioma.pdf
The Emerging Role of Antifolates in the treatment of malignant mesothelioma.pdf
Variability in Mesothelioma Tumor Response classification.pdf
OTHER CANCER ARTICLES
A
High Rate if Venous Thromboembolism in a Multi-Institutional Phase
II Trial of Weekly Intravenous Gemcitabine.pdf
A
Phase II Trial of Suramin Monthly.pdf
A
Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in
Hormone-Refractory Prostate Cancer.pdf
A
Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor
BMS-275291.pdf
Activities
and Accomplishments of the Cancer and Leukemia Group B Genitourinary
Committee.pdf
Adrenal
Amdrogen Levels as Predictors of Outcome in Prostate Cancer Patients
Treated with Ketoconazole Plus Antiandrogen Withdrawel.pdf
Dose-Ranging
Study of the Safety and Pharmacokinetics of Atrasentan in Patients
with Refractory Malignacies.pdf
Gene
Expression Profiling of Favorable Histology Wilms Tumors and Its
Correlation with Clinical Features.pdf
Gene
Expression Profiling of Renal Medullary Carcinoma.pdf
Hypoxia-Inducible
Factor-1 Target Genes as Indicators of Tumor Vessel Response to
Vascular Endothelial Growth Factor Inhibition.pdf
Inverse
Correlation between Body Mass Index and Clinical Outcomes in Men
with Advanced Castration-Recurrent Prostate Cancer.pdf
Neoadjuvent
Chemotherapy plus Cystectomy Compared with Cystectomy Alone for
Locally Advanced Bladder Cancer.pdf
Predictors
of Prostate Cancer Tissue Acquisition by an Undirected Core Bone
Marrow Biopsy in Metastatic Castration-Resistant Prostate Caner.pdf
Quality
of Life Impact of Three Different Doses of Suramin in Patients with
Metastatic Hormone-Refractory Prostate Carcinoma.pdf
Safety
and Biological Activity of Repeated Doses of Recombinant Human Flt3
Ligand in Patients.pdf
The
Prognostic Significance of Plasma Interleukin-6 Levels in Patients
with Metastatic Hormone-Refractory Prostate Cancer.pdf
Chair and Medical Director
Developmental Therapeutics and
Co-Chair GU Committee
US Oncology Research
c/o Comprehensive Cancer Centers of NV
3730 S. Eastern Ave.
Las Vegas, NV 89169
888.680.6376
nvogelzang@mdmeso.com
